BioSpace News Archive

Biotech Beach

Decipher Biosciences Announces its Genomic Data Featured at 2019 Genitourinary Conference in Multiple Prostate Cancer Presentations

Decipher Biosciences, a leader in the field of urologic cancer genomics, announced that it will present results from seven studies featuring its Decipher® Prostate and Bladder Cancer Classifier Tests and Decipher Genomics Resource Information Database.

February 14, 2019

·

3 min read

Business

AbCellera Announces Multi-Target Partnership Agreement with a Top 5 Global Pharma

Multi-year agreement will provide access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.

February 14, 2019

·

2 min read

Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride

Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk

February 14, 2019

·

13 min read

Genetown

Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System

Expansion of CorPath GRX into neurovascular intervention could mark first step in revolutionizing stroke treatment

February 14, 2019

·

6 min read

Pharm Country

NeoTract Announces Expanded Coverage for UroLift System Treatment for Patients with Enlarged Prostate

Favorable Coverage Decisions Broaden Access to This Minimally Invasive Treatment That Provides Rapid Relief and Recovery from Symptoms

February 14, 2019

·

5 min read

Business

Quest Diagnostics Reports Fourth Quarter And Full Year 2018 Financial Results; Provides Guidance For Full Year 2019

Fourth quarter diluted EPS of $0.92 on a reported basis, down 49.5% from 2017 which included a tax benefit recorded as a result of the Tax Cuts and Jobs Act (TCJA); and $1.36 on an adjusted basis excluding amortization, down 2.9% from 2017

February 14, 2019

·

20 min read

Drug Development

Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects

Lipocine Inc. announced that the U.S. Food & Drug Administration indicated that the Phase 2 clinical study of LPCN 1144 in non-alcoholic steatohepatitis with biopsy confirmed NASH subjects may proceed in response to the Company’s Investigational New Drug application.

February 14, 2019

·

4 min read

Drug Development

Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials

Research Program Expanded Based on Promising Data Shown with KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib), Chemotherapy and Anti-Hormone Agents in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

February 14, 2019

·

43 min read

FDA

Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease

Ocugen, Inc. announced the U.S. Food and Drug Administration granted orphan drug designation for OCU400, Ocugen’s novel gene therapy, for the treatment of NR2E3 mutation-associated retinal degenerative disease.

February 14, 2019

·

4 min read

Deals

Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering

Inovio Pharmaceuticals, Inc. announced the pricing of its offering of $65.0 million aggregate principal amount of 6.50% convertible senior notes due 2024.

February 14, 2019

·

5 min read